BioAge Labs, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-09-03. It has amended it 2 times. It filed its final prospectus on 2024-09-26, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We have been approved to list our common stock on the Nasdaq Global Select Market under the symbol BIOA.From the 424B4 filed 2024-09-26
Shares offered
We are offering 11,000,000 shares of our common stock.From the 424B4 filed 2024-09-26
Offering price
The initial public offering price is $18.00 per share.From the 424B4 filed 2024-09-26
Use of proceeds
We currently intend to use the net proceeds from this offering and the concurrent private placement, together with our existing cash and cash equivalents, to advance the continued development of azelaprag for the treatment of obesity in our ongoing STRIDES clinical trial in combination with tirzepatide, a Phase 2 clinical trial in combination with semaglutide, and the manufacture of drug products to support Phase 3 clinical trials sufficient for registration; the initiationFrom the 424B4 filed 2024-09-26
Net loss or income
Our net losses were $63.9 million and $39.7 million for the years ended December 31, 2023 and 2022, respectively, and $26.6 million and $28.3 million for the six months ended June 30, 2024 and 2023, respectively.From the S-1/A filed 2024-09-25
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-03 | Registration statement filed | S-1 |
| 2024-09-18 | Registration statement amended | S-1/A |
| 2024-09-25 | Registration statement amended | S-1/A |
| 2024-09-26 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for BioAge Labs, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.